Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported 16.04M in Outstanding Shares in April of 2024. Data for Alaunos Therapeutics | ZIOP - Outstanding Shares including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
Twitterhttps://meyka.com/licensehttps://meyka.com/license
AI-powered price forecasts for ZIOP stock across different timeframes including weekly, monthly, yearly, and multi-year predictions.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $49.1M in Market Capitalization this December of 2025, considering the latest stock price and the number of outstanding shares.Data for Alaunos Therapeutics | ZIOP - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $0 in Cost of Sales for its fiscal quarter ending in September of 2024. Data for Alaunos Therapeutics | ZIOP - Cost Of Sales including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $3.72M in Assets for its fiscal quarter ending in September of 2025. Data for Alaunos Therapeutics | ZIOP - Assets including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $-21.02M in EBITDA for its fiscal quarter ending in March of 2021. Data for Alaunos Therapeutics | ZIOP - Ebitda including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $10.99M in Debt for its fiscal quarter ending in March of 2023. Data for Alaunos Therapeutics | ZIOP - Debt including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $-755K in Operating Profit for its fiscal quarter ending in December of 2024. Data for Alaunos Therapeutics | ZIOP - Operating Profit including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported 1.76 in Dividend Yield for its fiscal quarter ending in June of 2020. Data for Alaunos Therapeutics | ZIOP - Dividend Yield including historical, tables and charts were last updated by Trading Economics this last November in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $0 in Loan Capital for its fiscal quarter ending in December of 2024. Data for Alaunos Therapeutics | ZIOP - Loan Capital including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $-742K in Net Income for its fiscal quarter ending in December of 2024. Data for Alaunos Therapeutics | ZIOP - Net Income including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $2K in Sales Revenues for its fiscal quarter ending in March of 2025. Data for Alaunos Therapeutics | ZIOP - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last November in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $-1.04M in EBIT for its fiscal quarter ending in June of 2025. Data for Alaunos Therapeutics | ZIOP - Ebit including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $2.68M in Current Assets for its fiscal quarter ending in September of 2025. Data for Alaunos Therapeutics | ZIOP - Current Assets including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $759K in Operating Expenses for its fiscal quarter ending in December of 2024. Data for Alaunos Therapeutics | ZIOP - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $921K in Current Liabilities for its fiscal quarter ending in September of 2025. Data for Alaunos Therapeutics | ZIOP - Current Liabilities including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $843K in Trade Creditors for its fiscal quarter ending in September of 2025. Data for Alaunos Therapeutics | ZIOP - Trade Creditors including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $2K in Trade Debtors for its fiscal quarter ending in June of 2025. Data for Alaunos Therapeutics | ZIOP - Trade Debtors including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $845K in Selling and Administration Expenses for its fiscal quarter ending in December of 2024. Data for Alaunos Therapeutics | ZIOP - Selling And Administration Expenses including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported 1 in Employees for its fiscal year ending in December of 2023. Data for Alaunos Therapeutics | ZIOP - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported 16.04M in Outstanding Shares in April of 2024. Data for Alaunos Therapeutics | ZIOP - Outstanding Shares including historical, tables and charts were last updated by Trading Economics this last December in 2025.